pp1

PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.

Okadaic acid is a potent polyether marine toxin that primarily accumulates in the digestive glands of marine mollusks. It is a highly effective and selective inhibitor of protein phosphatases (PPs). By inhibiting these phosphatases, okadaic acid increases the phosphorylation levels of various proteins, acts as a tumor promoter, and induces tau protein phosphorylation. It can be used to establish models of Alzheimer’s disease and skin cancer.

3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.

1-NM-PP1 (PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.

1-Naphthyl PP1 (1-NA-PP 1) is a selective Src inhibitor, targeting v-Src and c-Fyn, c-Abl, CDK2, and CAMK II with IC50 values of 1.0, 0.6, 0.6, 18, and 22 μM, respectively.

3BrB-PP1 is an ATP-competitive analog that exhibits specific inhibitory activity towards protein kinase, particularly effective against protein kinases with mutations in the ATP-binding pocket, such as the Thr97 mutation within Sty1's ATP-binding pocket.

3-IN-PP1, a potent protein kinase D (PKD) inhibitor, exhibits pan-PKD inhibitory activity with IC50 values of 108 nM for PKD1, 94 nM for PKD2, and 108 nM for PKD3. Additionally, it serves as a broad-spectrum anticancer agent by inhibiting the growth of various tumor cells. 3-IN-PP1 is utilized in cancer research [1].

1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of Src family kinases v-Src.

DSPE-PEG1000-PP1 is a PEG compound composed of DSPE and the PP1 peptide. The PP1 peptide targets inflammatory atherosclerotic plaques. DSPE-PEG1000-PP1 is suitable for drug delivery applications.

DSPE-PEG5000-PP1 is a PEG compound composed of DSPE and the PP1 peptide, which targets inflammatory atherosclerotic plaques. It can be used for drug delivery.

DSPE-PEG2000-PP1 is a PEG compound composed of DSPE and the PP1 peptide. The PP1 peptide specifically targets inflammatory atherosclerotic plaques. DSPE-PEG2000-PP1 is utilized in drug delivery applications.

SMAPP1 is an activator of protein phosphatase 1 (PP1). SMAPP1 induces PP1 activity in vitro and activates latent HIV-1 provirus in cultured and primary T cells.

2OH-BNPP1 is a BUB1 kinase, a Ser/Thr kinase inhibitor, it used for the treatment of cancer.

ENPP1 inhibitor 32 is an ENPP1 inhibitor with antitumor activity.

PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , also inhibits DNA-PK (IC50: 60 nM).

ENPP1 Inhibitor C is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor with potential anticancer activity for the study of triple-negative breast cancer.

NPP1-IN-1 is a highly potent inhibitor of NPP enzymes, effectively inhibiting NPP1 with an IC 50 value of 0.15 μM and NPP3 with an IC 50 value of 40 μM [1].

ENPP1 inhibitor 43 is a novel small molecule for cancer immunotherapy.

[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist, exhibiting a binding affinity with an IC50 of 0.24 nM for the hY5 receptor, and significantly stimulates food intake [1].

PP13 is an antimicrobial peptide with efficacy against both Gram-negative and Gram-positive bacteria, displaying minimum inhibitory concentrations (MIC) of 16.7 µM for E. coli, 13.3 µM for B. subtilis, 23.3 µM for S. aureus, 8.0 µM for S. lutea, and 9.0 µM for B. pumilus [1].

PP102, an antimicrobial peptide, exhibits activity against gram-positive bacteria, including B. subtilis (MIC: 25 µM), S. aureus (MIC: 13.3 µM), S. lutea (MIC: 63 µM), and B. pumilus (MIC: 23 µM) [1].

PP113 is an antimicrobial peptide with activity against both Gram-negative and Gram-positive bacteria, exhibiting minimum inhibitory concentrations (MICs) of 73.3 µM for E. coli, 23.3 µM for B. subtilis, 13 µM for S. aureus, 16.7 µM for S. lutea, and 23.3 µM for B. pumilus [1].

DPP1-IN-1 (compound 1) serves as a potent DPP1 inhibitor and is utilized in the study of bronchiectasis [1].

DPP1-IN-1 hydrate, a DPP1 inhibitor (IC 50: 1.6 nM), exhibits excellent bioavailability and pharmacokinetic properties, making it suitable for investigating inflammatory diseases [1].